DaVita (DVA) Stock Price, News & Analysis

Company Overview

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Key Stats

• Today's Range: $156.86 to $161.89
• 50-Day Range: $139.81 to $165.19
• 52-Week Range: $97.31 to $168.50
• Volume: 997,774 shs
• Average Volume: 996,926 shs
• Market Capitalization: $13.23 billion
• P/E Ratio: 17.41
• Dividend Yield: N/A
• Price Target: $161.80
• Consensus Rating: Hold

DaVita Stock Analysis - MarketRank™

DaVita scored higher than 86% of companies evaluated by MarketBeat, and ranked 159th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

DaVita has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

DaVita has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 15.76%

Earnings Growth

Earnings for DaVita are expected to grow by 15.76% in the coming year, from $9.71 to $11.24 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DaVita is 17.41, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.33.

Price to Earnings Ratio vs. Sector

The P/E ratio of DaVita is 17.41, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 134.37.

Price to Earnings Growth Ratio

DaVita has a PEG Ratio of 0.89. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

DaVita has a P/B Ratio of 22.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.46% of the float of DaVita has been sold short.

Short Interest Ratio / Days to Cover

DaVita has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in DaVita has recently decreased by 0.47%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DaVita does not currently pay a dividend.

Dividend Growth

DaVita does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.06

Percentage of Shares Shorted

5.46% of the float of DaVita has been sold short.

Short Interest Ratio / Days to Cover

DaVita has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in DaVita has recently decreased by 0.47%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.20

News Sentiment

DaVita has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for DaVita this week, compared to 8 articles on an average week.

Search Interest

Only 7 people have searched for DVA on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.

MarketBeat Follows

10 people have added DaVita to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, DaVita insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,807,161.00 in company stock.

Percentage Held by Insiders

Only 2.00% of the stock of DaVita is held by insiders.

Percentage Held by Institutions

90.12% of the stock of DaVita is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DVA Stock Analysis - Frequently Asked Questions

How have DVA shares performed this year?

DaVita's stock was trading at $104.76 on January 1st, 2024. Since then, DVA shares have increased by 54.1% and is now trading at $161.40.
View the best growth stocks for 2024 here.

How were DaVita's earnings last quarter?

DaVita Inc. (NYSE:DVA) issued its quarterly earnings data on Tuesday, October, 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.76 by $0.17. DaVita's revenue for the quarter was up 4.6% compared to the same quarter last year.
Read the conference call transcript.

Does DaVita have any subsidiaries?

DaVita subsidiaries include Northwest Physicians Network, Purity Dialysis, Family Health Care of Central Florida, Healthcare Partners, Gambro Healthcare, Aberdeen Dialysis LLC, Accountable Kidney Care LLC, and others.

Who are DaVita's major shareholders?

DaVita's top institutional investors include State Street Corp (2.94%), Geode Capital Management LLC (1.42%), Charles Schwab Investment Management Inc. (0.61%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.50%). Insiders that own company stock include Javier Rodriguez, Michael David Staffieri, Joel Ackerman, Kathleen Alyce Waters, James O Hearty, Charles Berg, John M Nehra, Phyllis R Yale, Barbara J Desoer, Pamela M Arway and Paula A Price.
View institutional ownership trends.

How do I buy shares of DaVita?

Shares of DVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of DaVita own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DaVita investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 10/29/2024
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/11/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Miscellaneous health & allied services, not elsewhere classified
• Sub-Industry: Health Care Services
• Current Symbol: NYSE:DVA
• CUSIP: 23918K10
• CIK: 927066
• Web: www.davita.com
• Phone: (720) 631-2100
• Fax: 302-636-5454
• Employees: 70,000
• Year Founded: 1999

Price Target and Rating

• Average Stock Price Target: $161.80
• High Stock Price Target: $175.00
• Low Stock Price Target: $145.00
• Potential Upside/Downside: +0.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $9.27
• Trailing P/E Ratio: 17.41
• Forward P/E Ratio: 16.62
• P/E Growth: 0.9
• Net Income: $691.53 million
• Net Margins: 6.53%
• Pretax Margin: 11.10%
• Return on Equity: 88.18%
• Return on Assets: 4.88%

Debt

• Debt-to-Equity Ratio: 15.78
• Current Ratio: 1.37
• Quick Ratio: 1.33

Sales & Book Value

• Annual Sales: $12.67 billion
• Price / Sales: 1.04
• Cash Flow: $16.92 per share
• Price / Cash Flow: 9.54
• Book Value: $13.63 per share
• Price / Book: 11.84

Miscellaneous

• Outstanding Shares: 82,000,000
• Free Float: 80,360,000
• Market Cap: $13.23 billion
• Optionable: Optionable
• Beta: 0.89